Thomas Mitchell is a global biotech executive who has recently relocated to Adelaide, Australia, after spending time leading drug development programs in Boston, USA and Cambridge, UK. He works in an interesting area of medicine - developing microbial therapies for many gut-related conditions, including inflammatory bowel disease. Previously, Thomas held important positions at Finch Therapeutics and Microbiotica, both microbial therapy companies. 

Having grown up in Newcastle, Australia, Thomas has returned to be CEO of BiomeBank and intends to build an Australian-based microbiome biotechnology company to treat unmet medical need globally, with an immediate focus on the APAC region. 

In this episode, Thomas and Daniel broached a few topics, including Thomas's journey, his vision of where Biomebank could be, the benefits of the drug industry, growing and scaling companies, his beliefs around leadership, plus much more.

If you enjoy this episode, please share it with your friends and colleagues, and check us out on synergyiq.com.au. 

Join the conversation on Synergy IQ LinkedIn, Facebook and Instagram (@synergyiq) and please support other leaders by liking, subscribing and sharing this podcast.   

Access SynergyIQ Website to get to know more about us.   

Say hello to our host Daniel on LinkedIn.